Division of Hematology-Oncology, Children's Hospital of Zhejiang University School of Medicine and Zhejiang Key Laboratory for Neonatal Diseases, Hangzhou, PR China.
Leuk Lymphoma. 2010 Dec;51(12):2262-9. doi: 10.3109/10428194.2010.518653. Epub 2010 Oct 7.
Data on childhood acute myeloid leukemia (AML) in developing countries are limited. Herein we report the outcome of childhood AML treated with modified NPCLC-AML97 in our institution from 1997 to 2005. One hundred and eighty-five children with newly diagnosed AML were admitted. The 7-year overall survival (OS) and event free survival (EFS) rates for the whole cohort were 33.1 ± 4.1% and 31.2 ± 3.7%, respectively. Sixty patients (32.4%) refused chemotherapy and 123 were eligible for protocol evaluation. Among eligible patients, 111 (90.2%) achieved complete remission (CR). The estimated 7-year OS and EFS rates were 50.2 ± 5.5% and 46.9 ± 5.1%, respectively. APL was more curable than non-APL (7-year EFS: 63.5 ± 7.9% vs. 35.9 ± 6.3%, p = 0.005). Thirty-one patients (25.2%) relapsed, but no central nervous system leukemia was observed. Although the cure rate of childhood AML in China was low, the treatment outcome for patients who could adhere to the treatment protocol was satisfactory.
发展中国家儿童急性髓系白血病（AML）的数据有限。在此，我们报告了我们机构在 1997 年至 2005 年期间使用改良 NPCLC-AML97 方案治疗儿童 AML 的结果。共收治了 185 例新诊断为 AML 的患儿。全组患儿的 7 年总生存（OS）率和无事件生存（EFS）率分别为 33.1±4.1%和 31.2±3.7%。60 例患儿（32.4%）拒绝化疗，123 例符合方案评估。在符合条件的患者中，111 例（90.2%）达到完全缓解（CR）。估计 7 年 OS 率和 EFS 率分别为 50.2±5.5%和 46.9±5.1%。APL 比非 APL 更具可治愈性（7 年 EFS：63.5±7.9% vs. 35.9±6.3%，p=0.005）。31 例患儿（25.2%）复发，但未观察到中枢神经系统白血病。尽管中国儿童 AML 的治愈率较低，但能坚持治疗方案的患者的治疗效果令人满意。
